Harpoon Therapeutics Inc

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct? (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies.  Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.

Merck

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP). Harpoon is now a wholly-owned subsidiary of Merck, and Harpoon's common stock will no longer be publicly traded or listed on the Nasdaq Stock Market. “We continue to augment and diversify our oncology pipeline with innovative approaches to help people with cancer worldwide,” said Dr. Dean Y. Li, pr.

Merck Completes Acquisition of Harpoon Therapeutics, Inc.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Harpoon Therapeutics, Inc. (NasdaqCM: HARP) to Merck & Co., Inc. (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Harpoon will receive $23.00 in cash for each share of Harpoon that they own. KSF is seeking to determine whether this consideration and the process that led to it are a.

HARPOON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Harpoon Therapeutics, Inc. - HARP

Shares of Harpoon Therapeutics Inc. (HARP) more than doubled Monday after Merck & Co. (MRK) agreed to buy the cancer drug researcher for about $680 million.

Merck Buys Harpoon Therapeutics To Expand Its Oncology Portfolio

MILWAUKEE , Jan. 8, 2024 /PRNewswire/ -- Ademi LLP is investigating Harpoon (Nasdaq: HARP)  for possible breaches of fiduciary duty and other violations of law in its transaction with Merck. Click here to learn how to join the https://www.ademilaw.com/case/harpoon-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Harpoon Therapeutics, Inc. has obtained a Fair Price in its transaction with Merck

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Harpoon Therapeutics, Inc. (NASDAQ: HARP) to Merck for $23.00 per share in cash is fair to Harpoon shareholders. Halper Sadeh encourages Harpoon shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Harpoon and its b.

HARP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Harpoon Therapeutics, Inc. Is Fair to Shareholders

Harpoon Therapeutics (NASDAQ: HARP ) stock is rocketing higher on Monday after Merck (NYSE: MRK ) announced plans to acquire the company. Merck is offering $23 per share for HARP stock.

Why Is Harpoon Therapeutics (HARP) Stock Up 111% Today?

Merck has struck a deal to buy clinical-stage immunotherapy company Harpoon Therapeutics for about $680 million.

Merck to Buy Harpoon Therapeutics for $680 Million

Merck & Co said on Monday it would buy cancer drug developer Harpoon Therapeutics for about $680 million, reinforcing its oncology portfolio with immunotherapies.

Merck to buy Harpoon Therapeutics for $680 million

RAHWAY, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Harpoon Therapeutics, Inc. (Nasdaq: HARP) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million. “At Merck, we continue to enhance our oncology pipeline through strategic acquisitions that compl.

Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline

Merck & Co Inc (NYSE:MRK) is close to acquiring Harpoon Therapeutics Inc, a cancer drug developer, for about $700 million to bolster its oncology portfolio. The proposed deal, which could value Harpoon at $23 per share, aligns with Merck's strategy to seek new growth opportunities as its top-selling cancer drug Keytruda faces future pricing pressures.

Merck close to acquiring cancer specialist Harpoon Therapeutics

Merck & Co is in advanced talks to buy cancer drugmaker Harpoon Therapeutics Inc for around $700 million, Bloomberg News reported on Sunday, citing people familiar with the matter.

Merck in talks to buy Harpoon Therapeutics for around $700 mln - Bloomberg News

James Bucher, J.D. joins as Chief Legal Officer Wendy Chang promoted to Chief People Officer SOUTH SAN FRANCISCO, Calif.

Harpoon Therapeutics Strengthens Leadership Team

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and an upcoming rapid oral presentation of updated interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine tumor types at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) being held in San Francisco, CA and virtually on January 25-27, 2024. HPN328 targets delta-like ligand 3 (DLL3) and is derived from Harpoon's proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient's own immune cells to kill tumor cells.

Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium

• HPN217 was well tolerated and demonstrated robust and durable clinical activity at doses ranging from 2.15 to 24 mg in heavily pre-treated patients, including patients with prior exposure to  BCMA-targeted therapy

Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)

Alpine Immune Sciences

Aurinia Pharmaceuticals

Journey Medical Corp

Lyra Therapeutics

Innovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio.

5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New Year

Harpoon Therapeutics, Inc. (HARP) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, HARP's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

Should You Buy Harpoon Therapeutics, Inc. (HARP) After Golden Cross?

Harpoon Therapeutics, Inc. (HARP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Harpoon Therapeutics, Inc. (HARP) Upgraded to Strong Buy: What Does It Mean for the Stock?

Centrus Energy

Pinduoduo Inc - ADR

PDD, HARP and LEU made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 5, 2023.

Best Momentum Stock to Buy for December 5th

Here, we discuss some reasons why investing in Harpoon Therapeutics (HARP) stock now may turn out to be a prudent move.

Is it a Good Idea to Invest in Harpoon (HARP) Stock Now?

The consensus price target hints at a 40.5% upside potential for Harpoon Therapeutics, Inc. (HARP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Harpoon Therapeutics, Inc. (HARP) Could Rally 40.5%: Here's is How to Trade

HPN328 is being advanced in a phase 1/2 study for the treatment of patients with neuroendocrine tumors; Promising interim data was released at ESMO 2023 medical conference. Updated data from the phase 1/2 study, using HPN328 for the treatment of patients with neuroendocrine tumors, is expected to be released in the 1st half of 2024. The global neuroendocrine tumors treatment market revenue is expected to increase to $6.33 billion by 2030.

Harpoon: HPN328 Data In 1st Half Of 2024 Makes This A Must Watch

Aquestive Therapeutics Inc

Avalo Therapeutics

Founder SPAC

Viad Corp

AQST, RBT, HARP, VVI and AVTX have been added to the Zacks Rank #1 (Strong Buy) List on November 21, 2023.

New Strong Buy Stocks for November 21st

Harpoon Therapeutics, Inc. (HARP) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Fast-paced Momentum Stock Harpoon Therapeutics, Inc. (HARP) Is Still Trading at a Bargain

The mean of analysts' price targets for Harpoon Therapeutics, Inc. (HARP) points to a 92.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 92.31% Upside in Harpoon Therapeutics, Inc. (HARP): Can the Stock Really Move This High?

1stdibs.com

EMCOR Group

Intel

Runway Growth Finance Corp

INTC, DIBS, HARP, EME and RWAY have been added to the Zacks Rank #1 (Strong Buy) List on November 14, 2023.

News for Harpoon Therapeutics Inc Stock (HARP)